dal-COVID Clinical Trial
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pre-clinical research has identified that the main protease (3CLMpro) of the SARS-CoV-2 virus is a key enzyme that plays a pivotal role in mediating viral replication and transcription. Dalcetrapib is a potential anti-viral treatment as it binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro, thereby inhibiting its activity and viral replication.
In December 2020. DalCor initiated the dal-COVID trial, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.
dal-COVID is a double-blind, placebo-controlled trial in patients with confirmed mild to moderate symptomatic COVID-19. The study will evaluate the efficacy and safety of three different doses of dalcetrapib compared to placebo in approximately 200 adult patients over a 10-day treatment period. Results are anticipated in Q1 2021.
More information can be found at clinicaltrials.gov: study number NCT04676867